ChroMedX Announces Collaborative Project with McMaster University
November 17, 2014
ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that it has reached an agreement with McMaster University on a collaborative project.
The collaborative Project led by ChroMedX Technical Advisory Board member Dr. Cynthia Balion will provide the necessary laboratory space for ChroMedX to handle and treat blood samples in the development of key algorithms for the HemoPalm spectroscopic analyser. In addition ChroMedX will be developing a device capable of measuring common preanalytical interferences in blood samples which will be of great value to the Canadian Institutes of Health Research’s Canadian Longitudinal Study on Aging (CLSA).
"The Company is proud to announce the collaborative project with Dr. Cynthia Balion at McMaster University. The Project will play an integral role in the development of the HemoPalm’s algorithms and we are excited to develop a device and support the CLSA initiative." said Dr. Wayne Maddever, ChroMedX President & CEO.
Technical Advisory Board member Dr. Cynthia Balion provides the scientific expertise and leadership for biospecimen collection, management and analysis within the CLSA study. Dr. Balion is also a clinical biochemist for the Hamilton Regional Laboratory Medicine Program (HRLMP) and co-investigator for the Canadian Longitudinal Study on Aging (CLSA) where she is the director of the Biorepository and Bioanalysis Centre.
The CLSA is a large, national, long-term study that follows 50,000 men and women between the ages of 45 and 85 for 20 years. As the most comprehensive study of health and aging in Canada, the CLSA collects information on the changing biological, medical, psychological, social, lifestyle and economic aspects of people's lives as they age.
Further information on the Canadian Longitudinal Study on Aging (CLSA) can be found on their website here: https://www.clsa-elcv.ca/
About ChroMedX Corp.
ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.
W. Clark Kent
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com
The security symbol, MNLIF, is part of the OTC Grey Market, where Monarch does not provide any reports and has no obligation to do so. There are no market makers under this symbol of this security. It is not listed, traded or quoted on any U.S. stock exchange or the OTC Markets. Trades in grey market stocks are reported by broker-dealers to their Self Regulatory Organization (SRO) and the SRO distributes the trade data to market data vendors and financial websites so investors can track price and volume. Since grey market securities are not traded or quoted on an exchange or interdealer quotation system, investor's bids and offers are not collected in a central spot so market transparency is diminished and best execution of orders is difficult.